BRIDGEBIO PHARMA INC
NASDAQ: BBIO (BridgeBio Pharma, Inc.)
Kemas kini terakhir: 18 jam lalu43.99
1.16 (2.71%)
| Penutupan Terdahulu | 42.83 |
| Buka | 42.63 |
| Jumlah Dagangan | 2,459,206 |
| Purata Dagangan (3B) | 3,144,636 |
| Modal Pasaran | 8,352,865,280 |
| Harga / Jualan (P/S) | 64.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 31 Jul 2025 |
| Margin Operasi (TTM) | -89.00% |
| EPS Cair (TTM) | -3.56 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -44.80% |
| Nisbah Semasa (MRQ) | 4.57 |
| Aliran Tunai Operasi (OCF TTM) | -500.42 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -261.20 M |
| Pulangan Atas Aset (ROA TTM) | -48.27% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | BridgeBio Pharma, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -3.5 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.80 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.97% |
| % Dimiliki oleh Institusi | 98.14% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Viking Global Investors Lp | 31 Mar 2025 | 22,055,375 |
| Kohlberg Kravis Roberts & Co. L.P. | 31 Mar 2025 | 19,260,971 |
| Aisling Capital Management Lp | 31 Mar 2025 | 6,068,125 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 76.00 (Wells Fargo, 72.77%) | Beli |
| Median | 56.00 (27.30%) | |
| Rendah | 49.00 (Wolfe Research, 11.39%) | Beli |
| Purata | 60.71 (38.01%) | |
| Jumlah | 7 Beli | |
| Harga Purata @ Panggilan | 40.25 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 30 Jun 2025 | 76.00 (72.77%) | Beli | 43.18 |
| B of A Securities | 25 Jun 2025 | 54.00 (22.76%) | Beli | 44.38 |
| Wolfe Research | 17 Jun 2025 | 49.00 (11.39%) | Beli | 40.07 |
| HC Wainwright & Co. | 09 Jun 2025 | 56.00 (27.30%) | Beli | 39.03 |
| 15 Apr 2025 | 53.00 (20.48%) | Beli | 34.24 | |
| Piper Sandler | 30 Apr 2025 | 63.00 (43.21%) | Beli | 38.36 |
| Scotiabank | 30 Apr 2025 | 55.00 (25.03%) | Beli | 38.36 |
| UBS | 30 Apr 2025 | 72.00 (63.67%) | Beli | 38.36 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HOMCY CHARLES J | - | 44.86 | -20,000 | -897,200 |
| MCCORMICK FRANK | - | 44.45 | -100,000 | -4,445,000 |
| VALANTINE HANNAH | - | 45.12 | -4,707 | -212,380 |
| Jumlah Keseluruhan Kuantiti Bersih | -124,707 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -5,554,580 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 44.89 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| HOMCY CHARLES J | Pengarah | 27 Jun 2025 | Dibuang (-) | 20,000 | 44.86 | 897,200 |
| VALANTINE HANNAH | Pengarah | 26 Jun 2025 | Jual (-) | 2,418 | 45.12 | 109,100 |
| VALANTINE HANNAH | Pengarah | 26 Jun 2025 | Jual (-) | 2,289 | 45.12 | 103,280 |
| MCCORMICK FRANK | Pengarah | 24 Jun 2025 | Jual automatik (-) | 100,000 | 44.45 | 4,445,000 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |